The latest report from business intelligence provider Visiongain offers comprehensive analysis of the global influenza vaccines market. Visiongain assesses that this market will generate revenues of $4.97 billion in 2017.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. Visiongain’s new study tells you and tells you NOW.
In this brand new 147 page report you find 64 in-Depth tables, charts and graphs – all unavailable elsewhere.
The report provides clear detailed insight into the global Influenza market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope Visiongain’s new investigation shows revenue predictions at overall world market, submarket, company, product and national level.
That study gives individual analysis for two influenza vaccine submarkets, which are further divided by vaccine technologies: • Trivalent Influenza Vaccines (TIV) • Quadrivalent Influenza Vaccines (QIV)
Our new analysis also shows you revenue predictions for the vaccines produced by these five market leaders: and their market share • Sanofi Pasteur • GSK • Seqirus • AstraZeneca • Protein Science Corporation. • Others
From 2017, large pharmaceutical companies and other biopharma specialists can prosper in that market. See how, discovering organisations’ potentials. Our report analyses the vaccines in research and development and assess their prospects once they enter the market. The R&D pipeline discusses: • Seasonal Influenza vaccines in development • Universal Influenza vaccines in development
The report includes forecasts and analysis of pipeline developments for the following specific vaccines • Fluzone / VaxiGrip • Seqirus • Fluarix / FluLaval • FluMist / Fluenz • FluBlok • Other
The study shows you prospects for those drug sales in developed and developing regions. There see individual revenue forecasts to 2027 for 11 countries: • United States • Japan • The EU 5 – Germany, France, United Kingdom, Italy and Spain. • Brazil, Russia, India and China.
Who should read this report? • Anyone within the influenza vaccines value chain. • Pharmaceutical companies • Vaccine manufacturers • Healthcare biotech companies • Generics and biosimilar producers • Drug delivery companies and other technology providers • Contract/clinical research organisations (CROs) • Pharma contract manufacturers, • Pharma/healthcare wholesale and distribution companies • Medical device companies • Healthcare diagnostics companies • R&D specialists • Business development managers • Marketing managers • Technologists • Suppliers • Investors • Banks • Government agencies • Contractors
Visiongain’s study is intended for anyone requiring commercial analyses for the influenza vaccines market and leading companies. You find data, trends and predictions.
Buy our report today Global Influenza Vaccines – World Industry Market Outlook 2017-2027: Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Analysis of Pipeline Developments For Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other. Avoid missing out by staying informed – get our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview
1.1 Global Influenza Vaccine Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to the World Influenza Vaccine Market
2.1 The Influenza Virus Kills over 500,000 People Every Year
2.2 Influenza has a Huge Social and Economic Burden on all Societies
2.3 The Influenza Virus Mutates Annually Rendering the Previous Year’s Vaccines Ineffective
2.3.1 All Current Influenza Vaccines are either Trivalent (TIV) or Quadrivalent (QIV)
2.3.2 The Antigenic Drift Mutation Causes Epidemics
2.3.3 The Antigenic Shift Mutation Causes Pandemics
2.4 An Epidemic or a Pandemic Outbreak?
2.4.1 Seasonal Influenza Epidemic (Local)
2.4.2 Pandemic Influenza (Worldwide): ‘A’ Subtype
2.4.3 Flu Vaccine Effectiveness
2.5 Key Influencers of the Influenza Vaccine Market
2.5.1 Governments and International Organisations
18.104.22.168 Every Year the World Health Organisation Identifies the Most Likely Strain of the Influenza Virus
22.214.171.124 The Governmental Stance of the Importance of Influenza Directly Drives the Market
126.96.36.199 The WHO’s “Influenza Vaccine Production Transfer Project” Affects Big Pharma’s Vaccine Sales
2.5.2 Leading Manufacturers
188.8.131.52 Sanofi Pasteur is the Market Leader
184.108.40.206 CSL Has Bought Novartis's Flu Vaccine Business Forming a New Infuenza Vaccine Company Seqirus
220.127.116.11 GSK is Now Third Placed in the Market
18.104.22.168 AstraZeneca’s Flumist Product is in Trouble
3. Influenza Vaccine World Market Outlook, 2017-2027
3.1 The World Influenza Market Performance, 2015
3.1.1 Growing Elderly Population
3.1.2 Paediatric Influenza Vaccines – High Demand Markets
3.1.3 Emerging Markets
3.2 The World Influenza Market Revenue Forecast for 2016-2027
3.3 The World Influenza Market: Industry Trends, 2017-2027
3.3.1 Demand Driven Trends
3.3.2 Supply Efficiency Affects Sales
3.3.3 Funding Trends
3.3.4 Protecting the Workforce of an Economy
4. TIV Vaccines will be Replaced by QIV Vaccines in the Near Future
4.1 Trivalent Influenza Vaccines (TIV)
4.2 Quadrivalent Vaccines (QIV)
4.3 Influenza Vaccines by TIV and QIV Type
5. Leading Influenza Vaccines: Revenue Predictions, 2017-2027
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email email@example.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico